Related references
Note: Only part of the references are listed.Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chenglong Chen et al.
CANCER LETTERS (2021)
Future Therapeutic Directions for Smac-Mimetics
Emma Morrish et al.
CELLS (2020)
Transient NK Cell Depletion Facilitates Pulmonary Osteosarcoma Metastases After Intravenous Inoculation in Athymic Mice
Michael A. Harris et al.
JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY (2020)
The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice
Michael A. Harris et al.
CANCERS (2020)
Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice
Tanmay M. Shekhar et al.
BMC CANCER (2019)
The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma
Marie-Francoise Heymann et al.
CELLULAR IMMUNOLOGY (2019)
Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy
D. Matthew Gianferante et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Re-calculating! Navigating through the osteosarcoma treatment roadblock
J. McGuire et al.
PHARMACOLOGICAL RESEARCH (2017)
Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
Shawn T. Beug et al.
NATURE COMMUNICATIONS (2017)
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
Roman Groisberg et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Drugs in early clinical development for the treatment of osteosarcoma
Marie-Francoise Heymann et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Metastatic osteosarcoma: a challenging multidisciplinary treatment
Cristina Meazza et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
IAP antagonists induce anti-tumor immunity in multiple myeloma
Marta Chesi et al.
NATURE MEDICINE (2016)
IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα
Tanmay M. Shekhar et al.
ONCOTARGET (2016)
TNFα promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated state
T. Mori et al.
ONCOGENE (2014)
Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues
Krupa J. Patel et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Serum tumor markers in pediatric osteosarcoma: a summary review
Yulia A. Savitskaya et al.
CLINICAL SARCOMA RESEARCH (2012)
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects
Katherine A. Janeway et al.
LANCET ONCOLOGY (2010)
MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), Amplified on Chromosome 9, Collaborate with p53 Deficiency in Mouse Osteosarcoma Progression
Ou Ma et al.
CANCER RESEARCH (2009)
Drug resistance and the solid tumor microenvironment
Olivier Tredan et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Brain metastasis in pediatric extracranial solid tumors: survey and literature review
R Kebudi et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells
QH Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Reciprocal regulation of polarized cytokine production by effector B and T cells
DP Harris et al.
NATURE IMMUNOLOGY (2000)
Share Paper
